Open AccessEffects of moxonidine on sympathetic nervous system activity: An update on metabolism, cardio, and other target-organ protection
Author(s) -
Eleni Karlafti,
Apostolos Hatzitolios,
Anastasios Karlaftis,
Maria Baltatzi,
Γεώργιος Κολιάκος,
Christos Savopoulos
Publication year - 2013
Publication title -
journal of pharmacy and bioallied sciences
Language(s) - English
Resource type - Journals
eISSN - 0976-4879
pISSN - 0975-7406
DOI - 10.4103/0975-7406.120067
Subject(s) - moxonidine , imidazoline receptor , medicine , pharmacology , sympathetic nervous system , agonist , adverse effect , sympathetic activity , blood pressure , receptor , heart rate
Moxonidine is the newest, second-generation, centrally acting antihypertensive agent. It has selective agonist activity at imidazoline I1 receptors and less adverse effects than the other centrally acting drugs. This fact authorizes the frequent use of moxonidine in clinical practice, as monotherapy or in combination with other antihypertensive agents. Also, moxonidine has beneficial effects in obese and metabolic syndrome and in target-organs, such as heart and kidneys.